跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XIGDUO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
XIGDUO
Authorized
STANDARD
XIGDUO
astrazeneca canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
bf1ae89207b1e4cd
Company
astrazeneca canada inc
Type
Standard
Approval Details
Approval Id
bf1ae89207b1e4cd
Drug Approval Canada Name
XIGDUO
Product Name
XIGDUO
Status
Marketed
Status Date
2016-02-08
Original Market Date
2016-02-08
Din
02449935
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.18
Atc Original
A10BD15 METFORMIN AND DAPAGLIFLOZIN
Atc Name
a 10 bd 15
Aig Number
0257650001
Company Name
astrazeneca canada inc
Company Address
1004 Middlegate Road, Suite 5000, Mississauga, Ontario, Canada, L4Y 1M4
Active Ingredients
METFORMIN HYDROCHLORIDE
850 MG
DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE)
5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
bf1ae89207b1e4cd
Type
Standard
Back to Health Canada Approvals